DE60335892D1 - Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht - Google Patents

Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht

Info

Publication number
DE60335892D1
DE60335892D1 DE60335892T DE60335892T DE60335892D1 DE 60335892 D1 DE60335892 D1 DE 60335892D1 DE 60335892 T DE60335892 T DE 60335892T DE 60335892 T DE60335892 T DE 60335892T DE 60335892 D1 DE60335892 D1 DE 60335892D1
Authority
DE
Germany
Prior art keywords
treatment
pharmaceutical composition
preventation
observance
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335892T
Other languages
English (en)
Inventor
Valerie Residence Le Compan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60335892D1 publication Critical patent/DE60335892D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60335892T 2002-10-31 2003-10-31 Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht Expired - Lifetime DE60335892D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213725A FR2846559B1 (fr) 2002-10-31 2002-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
PCT/FR2003/003262 WO2004042063A1 (fr) 2002-10-31 2003-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle ou l'obesite

Publications (1)

Publication Number Publication Date
DE60335892D1 true DE60335892D1 (de) 2011-03-10

Family

ID=32104388

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335892T Expired - Lifetime DE60335892D1 (de) 2002-10-31 2003-10-31 Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht

Country Status (12)

Country Link
US (3) US8859537B2 (de)
EP (1) EP1556489B1 (de)
JP (1) JP4852245B2 (de)
AT (1) ATE497003T1 (de)
AU (1) AU2003292310A1 (de)
CA (1) CA2503546C (de)
DE (1) DE60335892D1 (de)
DK (1) DK1556489T3 (de)
ES (1) ES2362092T3 (de)
FR (1) FR2846559B1 (de)
PT (1) PT1556489E (de)
WO (1) WO2004042063A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
ES2705027T3 (es) 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
EP3952852A4 (de) * 2019-04-09 2023-01-04 The Trustees of Columbia University in the City of New York Prophylaktische wirksamkeit von serotonin-4-rezeptoragonisten gegen stress
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU686580B2 (en) * 1992-11-03 1998-02-12 Lundbeck Research Usa, Inc. DNA encoding a human serotonin receptor (5-HT-4B) and uses thereof
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
ES2208870T3 (es) * 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
JP2002542287A (ja) * 1999-04-28 2002-12-10 レスピラトリウス アクチボラゲット 医 薬
GB9913850D0 (en) * 1999-06-14 1999-08-11 Janssen Pharmaceutica Nv Cloning and expression of a novel receptor
FR2811989A1 (fr) * 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Also Published As

Publication number Publication date
EP1556489B1 (de) 2011-01-26
CA2503546A1 (fr) 2004-05-21
JP2006520319A (ja) 2006-09-07
ATE497003T1 (de) 2011-02-15
EP1556489A1 (de) 2005-07-27
US8436021B2 (en) 2013-05-07
US20090124592A1 (en) 2009-05-14
US20130274293A1 (en) 2013-10-17
PT1556489E (pt) 2011-05-31
ES2362092T3 (es) 2011-06-28
FR2846559B1 (fr) 2007-06-15
DK1556489T3 (da) 2011-05-16
JP4852245B2 (ja) 2012-01-11
WO2004042063A8 (fr) 2005-08-11
WO2004042063A1 (fr) 2004-05-21
FR2846559A1 (fr) 2004-05-07
US8859537B2 (en) 2014-10-14
AU2003292310A1 (en) 2004-06-07
US9168250B2 (en) 2015-10-27
CA2503546C (fr) 2014-02-11
US20060116341A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
EA200401365A1 (ru) Способы лечения илеуса
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
NO20045056L (no) Fremgangsmater for behandling av hepatitt
DE602004017174D1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
NO20076405L (no) Anvendelse av 24-nor-UDCA
EP1844779A3 (de) Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne)
DE60335892D1 (de) Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
BR0314713A (pt) Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
ATE410172T1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes